MedTrace Logo

Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction

NCT02054390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 459

Last updated 2014-06-20

No results posted yet for this study

Summary

Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.

Conditions

Sponsors & Collaborators

  • Ankara University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02054390 on ClinicalTrials.gov